Evidence map›Paper›PMID 30361908›Full record

Observational studyPathology oncology research : POR2019

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).

Róbert Szász, Elvira Altai, Katalin Pál, Péter Dombi, János Iványi, János Jakucs, Natália Jóni, Árpád Illés, Ilona Tárkányi, László Szerafin and 6 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 1 country.

Róbert SzászDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary. szaszr@med.unideb.hu.ORCID http://orcid.org/0000-0003-1343-6017
Elvira AltaiVeszprém County Csolnoky Ferenc Hospital, Kórház u. 1, Veszprém, 8200, Hungary.
Katalin PálFejér County Szent György Hospital, Seregélyesi út 3, Székesfehérvár, 8000, Hungary.
Péter DombiDepartment of Hematology, Szent Borbála Hospital, Dózsa György út 77, Tatabánya, 2800, Hungary.
János IványiDepartment of Hematology, Vas County Markusovszky Hospital, Markusovszky L. u. 5, Szombathely, 9700, Hungary.
János JakucsDepartment of Internal Medicine, Békés County Pándy Kálmán Hospital, I, Semmelweis u. 1, Gyula, 5700, Hungary.
Natália JóniMarkhot Ferenc Hospital, Széchenyi u. 27-29, Eger, 3300, Hungary.
Árpád IllésDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
Ilona Tárkányi1st Department of Internal Medicine, Semmelweis University, Korányi Sándor u. 2/A, Budapest, 1083, Hungary.
László SzerafinDepartment of Haematology, Szabolcs-Szatmár-Bereg County Jósa András Hospital, Szent István u. 68, Nyíregyháza, 4400, Hungary.
Zsolt NagyII. Department of Internal Medicine, Semmelweis Hospital, Csabai kapu 9-11, Miskolc, 3529, Hungary.
Péter Farkas3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, Budapest, 1125, Hungary.
Ágnes NagyI. Department of Internal Medicine, University of Pécs, Ifjúság út 13, Pécs, 7624, Hungary.
Klára PiukovicsII. Department of Internal Medicine, University of Szeged, Korányi Fasor 6, Szeged, 6720, Hungary.
György UjjI. Department of Internal Medicine, Jász-Nagykun-Szolnok County Hetényi Géza Hospital, Tószegi út 21, Szolnok, 5004, Hungary.
Tamás Schneider"A" Department of Internal Medicine, National Institute of Oncology, Ráth György u. 7-9, Budapest, 1122, Hungary.
Semmelweis University · HUUniversity of Debrecen · HUBékés Megyei Központi Kórház · HUFejér Megyei Szent György Egyetemi Oktató Kórház · HUJahn Ferenc Dél-Pesti Kórház és Rendelőintézet · HUJósa András Múzeum · HUMarkusovszky Egyetemi Oktatókórház · HUNational Institute of Oncology · HUSzent Borbála Kórház · HUToldy Ferenc Kórház · HUUniversity of Pecs · HUUniversity of Szeged · HUUzsoki Hospital · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most common haematological malignancies exhibiting remarkable heterogeneity in clinical course. Rituximab added to standard chemotherapy has been proven to increase response rate and eventually survival among previously untreated CLL patients. CILI was an open-label, non-randomized, single arm, multicentric, observational study aimed to collect real-life effectiveness data for rituximab used according to the current label in combination with standard chemotherapy in previously untreated CLL patients. Overall response rates (ORR) in the entire study population as well as in various subgroups were estimated. Adverse events were recorded during the entire course of the study. A total number of 150 patients were enrolled by 15 Hungarian study sites. Out of these, 82 patients received 6 cycles of rituximab containing treatment. Overall response rates of 88.24% (CI

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedRituximabTreatment OutcomeRituximabChronic lymphocytic leukemiaOverall response rateRituximab

Identifiers

PMID30361908
PMCPMC6449280
OpenAlexW2898161535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.